Abstract
The ε4 allele of the apolipoprotein E (APOE4) is associated with an increased risk of developing Alzheimer’s disease (AD). Hence, several studies have compared the brain characteristics of APOE4 carriers versus non-carriers in presymptomatic stages to determine early AD biomarkers. The present review provides an overview on APOE4-related brain changes in cognitively normal individuals, focusing on the main neuroimaging biomarkers for AD, i.e. cortical beta-amyloid (Aβ) deposition, hypometabolism and atrophy. The most consistent findings are observed with Aβ deposition as most studies report significantly higher cortical Aβ load in APOE4 carriers compared with non-carriers. Fluorodeoxyglucose-positron emission tomography studies are rare and tend to show hypometabolism in brain regions typically impaired in AD. Structural magnetic resonance imaging findings are the most numerous and also the most discrepant, showing atrophy in AD-sensitive regions in some studies but contradicting results as well. Altogether, this suggests a graded effect of APOE4, with a predominant effect on Aβ over brain structure and metabolism. Multimodal studies confirm this view and also suggest that APOE4 effects on brain structure and function are mediated by both Aβ-dependent and Aβ-independent pathological processes. Neuroimaging studies on asymptomatic APOE4 carriers offer relevant information to the understanding of early pathological mechanisms of the disease, although caution is needed as to whether APOE4 effects reflect AD pathological processes, and are representative of these effects in non-carriers.
Similar content being viewed by others
References
Alexopoulos, P., Richter-Schmidinger, T., Horn, M., Maus, S., Reichel, M., Sidiropoulos, C., et al. (2011). Hippocampal volume differences between healthy young apolipoprotein E ε2 and ε4 carriers. Journal of Alzheimer’s Disease, 26(2), 207–210.
Bacskai, B. J., Frosch, M. P., Freeman, S. H., Raymond, S. B., Augustinack, J. C., Johnson, K. A., et al. (2007). Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Archives of Neurology, 64(3), 431–434.
Barboriak, D. P., Doraiswamy, P. M., Krishnan, K. R., Vidyarthi, S., Sylvester, J., & Charles, H. C. (2000). Hippocampal sulcal cavities on MRI: relationship to age and apolipoprotein E genotype. Neurology, 54(11), 2150–2153.
Berlau, D. J., Corrada, M. M., Head, E., & Kawas, C. H. (2009). APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology, 72(9), 829–834.
Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., et al. (2000). Patterns of brain activation in people at risk for Alzheimer’s disease. The New England Journal of Medicine, 343(7), 450–456.
Bu, G. (2009). Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nature Reviews Neuroscience, 10(5), 333–344.
Bunce, D., Anstey, K. J., Cherbuin, N., Gautam, P., Sachdev, P., & Easteal, S. (2012). APOE genotype and entorhinal cortex volume in non-demented community-dwelling adults in midlife and early old age. Journal of Alzheimer’s Disease, 30(4), 935–942.
Burggren, A. C., Zeineh, M. M., Ekstrom, A. D., Braskie, M. N., Thompson, P. M., Small, G. W., et al. (2008). Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers. NeuroImage, 41(4), 1177–1183.
Chen, K., Reiman, E. M., Alexander, G. E., Caselli, R. J., Gerkin, R., Bandy, D., et al. (2007). Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. The American Journal of Psychiatry, 164(6), 916–921.
Chen, K., Ayutyanont, N., Langbaum, J. B. S., Fleisher, A. S., Reschke, C., Lee, W., et al. (2012). Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ε4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares. NeuroImage, 60(4), 2316–2322.
Chételat, G., & Fouquet, M. (2013). Neuroimaging biomarkers for Alzheimer’s disease in asymptomatic APOE4 carriers. Revue Neurologique, 169(10), 729–736.
Chiang, G. C., Insel, P. S., Tosun, D., Schuff, N., Truran-Sacrey, D., Raptentsetsang, S. T., et al. (2010). Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology, 75(22), 1976–1981.
Chiang, G. C., Insel, P. S., Tosun, D., Schuff, N., Truran-Sacrey, D., Raptentsetsang, S. T., et al. (2011). Impact of apolipoprotein E4-cerebrospinal fluid β-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimer’s & Dementia, 7(5), 514–520.
Clark, C. M., Schneider, J. A., Bedell, B. J., Beach, T. G., Bilker, W. B., Mintun, M. A., et al. (2011). Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA, the Journal of the American Medical Association, 305(3), 275–283.
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., et al. (2012). Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurology, 11(8), 669–678.
Cohen, R. M., Small, C., Lalonde, F., Friz, J., & Sunderland, T. (2001). Effect of apolipoprotein E genotype on hippocampal volume loss in aging healthy women. Neurology, 57(12), 2223–2228.
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261(5123), 921–923.
Dean, D. C., 3rd, Jerskey, B. A., Chen, K., Protas, H., Thiyyagura, P., Roontiva, A., et al. (2014). Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurology, 71(1), 11–22.
Den Heijer, T., Oudkerk, M., Launer, L. J., van Duijn, C. M., Hofman, A., & Breteler, M. M. B. (2002). Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. Neurology, 59(5), 746–748.
Dennis, E. L., & Thompson, P. M. (2014). Functional brain connectivity using fMRI in aging and Alzheimer’s disease. Neuropsychology Review, 24(1), 49–62.
Dennis, N. A., Browndyke, J. N., Stokes, J., Need, A., Burke, J. R., Welsh-Bohmer, K. A., et al. (2010). Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers. Alzheimer’s & Dementia, 6(4), 303–311.
Donix, M., Burggren, A. C., Suthana, N. A., Siddarth, P., Ekstrom, A. D., Krupa, A. K., et al. (2010a). Longitudinal changes in medial temporal cortical thickness in normal subjects with the APOE-4 polymorphism. NeuroImage, 53(1), 37–43.
Donix, M., Burggren, A. C., Suthana, N. A., Siddarth, P., Ekstrom, A. D., Krupa, A. K., et al. (2010b). Family history of Alzheimer’s disease and hippocampal structure in healthy people. The American Journal of Psychiatry, 167(11), 1399–1406.
Donix, M., Small, G. W., & Bookheimer, S. Y. (2012). Family history and APOE-4 genetic risk in Alzheimer’s disease. Neuropsychology Review, 22(3), 298–309.
Du, A.-T., Schuff, N., Chao, L. L., Kornak, J., Jagust, W. J., Kramer, J. H., et al. (2006). Age effects on atrophy rates of entorhinal cortex and hippocampus. Neurobiology of Aging, 27(5), 733–740.
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., Dekosky, S. T., Barberger-Gateau, P., et al. (2010). Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurology, 9(11), 1118–1127.
Ellis, K. A., Lim, Y. Y., Harrington, K., Ames, D., Bush, A. I., Darby, D., et al. (2013). Decline in cognitive function over 18 months in healthy older adults with high amyloid-β. Journal of Alzheimer’s Disease, 34(4), 861–871.
Espeseth, T., Westlye, L. T., Fjell, A. M., Walhovd, K. B., Rootwelt, H., & Reinvang, I. (2008). Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4. Neurobiology of Aging, 29(3), 329–340.
Fan, M., Liu, B., Zhou, Y., Zhen, X., Xu, C., Jiang, T., et al. (2010). Cortical thickness is associated with different apolipoprotein E genotypes in healthy elderly adults. Neuroscience Letters, 479(3), 332–336.
Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., et al. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. a meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA, the Journal of the American Medical Association, 278(16), 1349–1356.
Fennema-Notestine, C., Panizzon, M. S., Thompson, W. R., Chen, C.-H., Eyler, L. T., Fischl, B., et al. (2011). Presence of ApoE ε4 allele associated with thinner frontal cortex in middle age. Journal of Alzheimer’s Disease, 26(Suppl 3), 49–60.
Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., Smith, S. M., et al. (2009). Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proceedings of the National Academy of Sciences of the United States of America, 106(17), 7209–7214.
Filippini, N., Ebmeier, K. P., MacIntosh, B. J., Trachtenberg, A. J., Frisoni, G. B., Wilcock, G. K., et al. (2011). Differential effects of the APOE genotype on brain function across the lifespan. NeuroImage, 54(1), 602–610.
Fjell, A. M., Westlye, L. T., Grydeland, H., Amlien, I., Espeseth, T., Reinvang, I., et al. (2014a). Accelerating cortical thinning: unique to dementia or universal in aging? Cerebral Cortex, 24(4), 919–934.
Fjell, A. M., McEvoy, L., Holland, D., Dale, A. M., Walhovd, K. B., & Alzheimer’s Disease Neuroimaging Initiative. (2014b). What is normal in normal aging? Effects of aging, amyloid and Alzheimer’s disease on the cerebral cortex and the hippocampus. Progress in Neurobiology [in press].
Fleisher, A. S., Chen, K., Liu, X., Ayutyanont, N., Roontiva, A., Thiyyagura, P., et al. (2013). Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiology of Aging, 34(1), 1–12.
Gallagher, M., & Koh, M. T. (2011). Episodic memory on the path to Alzheimer’s disease. Current Opinion in Neurobiology, 21(6), 929–934.
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., et al. (2011). APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular Psychiatry, 16(9), 903–907.
Gold, B. T., Johnson, N. F., Powell, D. K., & Smith, C. D. (2012). White matter integrity and vulnerability to Alzheimer’s disease: preliminary findings and future directions. Biochimica et Biophysica Acta, 1822(3), 416–422.
Han, S. D., Houston, W. S., Jak, A. J., Eyler, L. T., Nagel, B. J., Fleisher, A. S., et al. (2007). Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response. Neurobiology of Aging, 28(2), 238–247.
Hinrichs, A. L., Mintun, M. A., Head, D., Fagan, A. M., Holtzman, D. M., Morris, J. C., et al. (2010). Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer’s disease. Biological Psychiatry, 67(6), 581–583.
Holtzman, D. M., Herz, J., & Bu, G. (2012). Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine, 2(3), a006312.
Honea, R. A., Vidoni, E., Harsha, A., & Burns, J. M. (2009). Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. Journal of Alzheimer’s Disease, 18(3), 553–564.
Honea, R. A., Swerdlow, R. H., Vidoni, E. D., Goodwin, J., & Burns, J. M. (2010). Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology, 74(2), 113–120.
Honea, R. A., Swerdlow, R. H., Vidoni, E. D., & Burns, J. M. (2011). Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology, 76(9), 822–829.
Hostage, C. A., Roy Choudhury, K., Doraiswamy, P. M., Petrella, J. R., & Alzheimer’s Disease Neuroimaging Initiative. (2013). Dissecting the gene dose-effects of the APOE ε4 and ε2 alleles on hippocampal volumes in aging and Alzheimer’s disease. PLoS One, 8(2), e54483.
Hua, X., Hibar, D. P., Lee, S., Toga, A. W., Jack, C. R., Jr., Weiner, M. W., et al. (2010). Sex and age differences in atrophic rates: an ADNI study with n = 1368 MRI scans. Neurobiology of Aging, 31(8), 1463–1480.
Huang, Y. (2010). Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer’s disease. Trends in Molecular Medicine, 16(6), 287–294.
Huang, Y., & Mucke, L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell, 148(6), 1204–1222.
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., et al. (2008). Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain, 131(Pt 6), 1630–1645.
Jack, C. R., Jr., Petersen, R. C., Xu, Y. C., O’Brien, P. C., Waring, S. C., Tangalos, E. G., et al. (1998). Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer’s disease. Annals of Neurology, 43(3), 303–310.
Jagust, W. J., Landau, S. M., & Alzheimer’s Disease Neuroimaging Initiative. (2012). Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging. The Journal of Neuroscience, 32(50), 18227–18233.
Kantarci, K., Lowe, V., Przybelski, S. A., Weigand, S. D., Senjem, M. L., Ivnik, R. J., et al. (2012). APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology, 78(4), 232–240.
Kerchner, G. A., Berdnik, D., Shen, J. C., Bernstein, J. D., Fenesy, M. C., Deutsch, G. K., et al. (2014). APOE ε4 worsens hippocampal CA1 apical neuropil atrophy and episodic memory. Neurology, 82(8), 691–697.
Khan, W., Giampietro, V., Ginestet, C., Dell’Acqua, F., Bouls, D., Newhouse, S., Dobson, R., et al. (2014). No differences in hippocampal volume between carriers and non-carriers of the ApoE ε4 and ε2 alleles in young healthy adolescents. Journal of Alzheimer’s Disease, 40(1), 37–43.
Kim, J., Basak, J. M., & Holtzman, D. M. (2009). The role of apolipoprotein E in Alzheimer’s disease. Neuron, 63(3), 287–303.
Knickmeyer, R. C., Wang, J., Zhu, H., Geng, X., Woolson, S., Hamer, R. M., et al. (2014). Common variants in psychiatric risk genes predict brain structure at birth. Cerebral Cortex, 24(5), 1230–1246.
Knopman, D. S., Jack, C. R., Jr, Wiste, H. J., Lundt, E. S., Weigand, S. D., Vemuri, P., et al. (2014). (18) F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiology of Aging [in press].
Kok, E., Haikonen, S., Luoto, T., Huhtala, H., Goebeler, S., Haapasalo, H., & Karhunen, P. J. (2009). Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Annals of Neurology, 65(6), 650–657.
Kukolja, J., Thiel, C. M., Eggermann, T., Zerres, K., & Fink, G. R. (2010). Medial temporal lobe dysfunction during encoding and retrieval of episodic memory in non-demented APOE epsilon4 carriers. Neuroscience, 168(2), 487–497.
Langbaum, J. B. S., Chen, K., Caselli, R. J., Lee, W., Reschke, C., Bandy, D., et al. (2010). Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele. Archives of Neurology, 67(4), 462–468.
Leinonen, V., Alafuzoff, I., Aalto, S., Suotunen, T., Savolainen, S., Någren, K., et al. (2008). Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B. Archives of Neurology, 65(10), 1304–1309.
Lemaître, H., Crivello, F., Dufouil, C., Grassiot, B., Tzourio, C., Alpérovitch, A., et al. (2005). No epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects. NeuroImage, 24(4), 1205–1213.
Lim, Y. Y., Ellis, K. A., Pietrzak, R. H., Ames, D., Darby, D., Harrington, K., et al. (2012). Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology, 79(16), 1645–1652.
Lim, Y. Y., Ellis, K. A., Ames, D., Darby, D., Harrington, K., Martins, R. N., et al. (2013). Aβ amyloid, cognition, and APOE genotype in healthy older adults. Alzheimer’s & Dementia.
Lim, Y. Y., Maruff, P., Pietrzak, R. H., Ames, D., Ellis, K. A., Harrington, K., et al. (2014). Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease. Brain, 137(Pt 1), 221–231.
Lind, J., Larsson, A., Persson, J., Ingvar, M., Nilsson, L.-G., Bäckman, L., et al. (2006). Reduced hippocampal volume in non-demented carriers of the apolipoprotein E epsilon4: relation to chronological age and recognition memory. Neuroscience Letters, 396(1), 23–27.
Liu, Y., Paajanen, T., Westman, E., Wahlund, L.-O., Simmons, A., Tunnard, C., et al. (2010a). Effect of APOE ε4 allele on cortical thicknesses and volumes: the addneuromed study. Journal of Alzheimer’s Disease, 21(3), 947–966.
Liu, Y., Paajanen, T., Westman, E., Zhang, Y., Wahlund, L.-O., Simmons, A., et al. (2010b). APOE ε2 allele is associated with larger regional cortical thicknesses and volumes. Dementia and Geriatric Cognitive Disorders, 30(3), 229–237.
Liu, C.-C., Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology, 9(2), 106–118.
Lowe, V. J., Weigand, S. D., Senjem, M. L., Vemuri, P., Jordan, L., Kantarci, K., et al. (2014). Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology [in press].
Lu, P. H., Thompson, P. M., Leow, A., Lee, G. J., Lee, A., Yanovsky, I., et al. (2011). Apolipoprotein E genotype is associated with temporal and hippocampal atrophy rates in healthy elderly adults: a tensor-based morphometry study. Journal of Alzheimer’s Disease, 23(3), 433–442.
Mathis, C. A., Kuller, L. H., Klunk, W. E., Snitz, B. E., Price, J. C., Weissfeld, L. A., et al. (2013). In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Annals of Neurology, 73(6), 751–761.
Matura, S., Prvulovic, D., Jurcoane, A., Hartmann, D., Miller, J., Scheibe, M., et al. (2014). Differential effects of the ApoE4 genotype on brain structure and function. NeuroImage, 89, 81–91.
Mielke, M. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Roberts, R. O., et al. (2012). Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology, 79(15), 1570–1577.
Mormino, E. C., Betensky, R. A., Hedden, T., Schultz, A. P., Ward, A., Huijbers, W., et al. (2014). Amyloid and APOE {varepsilon} 4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology [in press].
Morra, J. H., Tu, Z., Apostolova, L. G., Green, A. E., Avedissian, C., Madsen, S. K., et al. (2009). Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer’s disease, mild cognitive impairment, and elderly controls. NeuroImage, 45(1 Suppl), S3–15.
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., et al. (2010). APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Annals of Neurology, 67(1), 122–131.
Mosconi, L., Brys, M., Switalski, R., Mistur, R., Glodzik, L., Pirraglia, E., et al. (2007). Maternal family history of Alzheimer’s disease predisposes to reduced brain glucose metabolism. Proceedings of the National Academy of Sciences of the United States of America, 104(48), 19067–19072.
Mosconi, L., Mistur, R., Switalski, R., Brys, M., Glodzik, L., Rich, K., et al. (2009). Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology, 72(6), 513–520.
Mueller, S. G., & Weiner, M. W. (2009). Selective effect of age, Apo e4, and Alzheimer’s disease on hippocampal subfields. Hippocampus, 19(6), 558–564.
Mueller, S. G., Schuff, N., Raptentsetsang, S., Elman, J., & Weiner, M. W. (2008). Selective effect of Apo e4 on CA3 and dentate in normal aging and Alzheimer’s disease using high resolution MRI at 4 T. NeuroImage, 42(1), 42–48.
Murphy, K. R., Landau, S. M., Choudhury, K. R., Hostage, C. A., Shpanskaya, K. S., Sair, H. I., et al. (2013). Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth. NeuroImage, 78, 474–480.
O’Dwyer, L., Lamberton, F., Matura, S., Tanner, C., Scheibe, M., Miller, J., et al. (2012). Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. PLoS One, 7(11), e48895.
Plassman, B. L., Welsh-Bohmer, K. A., Bigler, E. D., Johnson, S. C., Anderson, C. V., Helms, M. J., et al. (1997). Apolipoprotein E epsilon 4 allele and hippocampal volume in twins with normal cognition. Neurology, 48(4), 985–989.
Protas, H. D., Chen, K., Langbaum, J. B. S., Fleisher, A. S., Alexander, G. E., Lee, W., et al. (2013). Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurology, 70(3), 320–325.
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., et al. (1996). Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. The New England Journal of Medicine, 334(12), 752–758.
Reiman, E. M., Uecker, A., Caselli, R. J., Lewis, S., Bandy, D., de Leon, M. J., et al. (1998). Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer’s disease. Annals of Neurology, 44(2), 288–291.
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., et al. (2004). Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proceedings of the National Academy of Sciences of the United States of America, 101(1), 284–289.
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., et al. (2005). Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proceedings of the National Academy of Sciences of the United States of America, 102(23), 8299–8302.
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., et al. (2009). Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America, 106(16), 6820–6825.
Rimajova, M., Lenzo, N. P., Wu, J.-S., Bates, K. A., Campbell, A., Dhaliwal, S. S., et al. (2008). Fluoro-2-deoxy-D-glucose (FDG)-PET in APOEepsilon4 carriers in the Australian population. Journal of Alzheimer’s Disease, 13(2), 137–146.
Risacher, S. L., Shen, L., West, J. D., Kim, S., McDonald, B. C., Beckett, L. A., et al. (2010). Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiology of Aging, 31(8), 1401–1418.
Rodrigue, K. M., Kennedy, K. M., Devous, M. D., Sr., Rieck, J. R., Hebrank, A. C., Diaz-Arrastia, R., et al. (2012). β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology, 78(6), 387–395.
Roe, C. M., Fagan, A. M., Grant, E. A., Hassenstab, J., Moulder, K. L., Maue Dreyfus, D., et al. (2013). Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology, 80(19), 1784–1791.
Roussotte, F. F., Gutman, B. A., Madsen, S. K., Colby, J. B., Narr, K. L., Thompson, P. M., et al. (2014). The apolipoprotein E epsilon 4 allele is associated with ventricular expansion rate and surface morphology in dementia and normal aging. Neurobiology of Aging, 35(6), 1309–1317.
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., et al. (2010). Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging, 31(8), 1275–1283.
Samuraki, M., Matsunari, I., Chen, W.-P., Shima, K., Yanase, D., Takeda, N., et al. (2012). Glucose metabolism and gray-matter concentration in apolipoprotein E ε4 positive normal subjects. Neurobiology of Aging, 33(10), 2321–2323.
Saunders, A. M., Schmader, K., Breitner, J. C., Benson, M. D., Brown, W. T., Goldfarb, L., et al. (1993). Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer’s disease and in other amyloid-forming diseases. Lancet, 342(8873), 710–711.
Scheinin, N. M., Wikman, K., Jula, A., Perola, M., Vahlberg, T., Rokka, J., et al. (2014). Cortical 11C-PIB Uptake is Associated with Age, APOE Genotype, and Gender in « Healthy Aging ». Journal of Alzheimer’s Disease [in press].
Schmidt, H., Schmidt, R., Fazekas, F., Semmler, J., Kapeller, P., Reinhart, B., et al. (1996). Apolipoprotein E e4 allele in the normal elderly: neuropsychologic and brain MRI correlates. Clinical Genetics, 50(5), 293–299.
Schuff, N., Woerner, N., Boreta, L., Kornfield, T., Shaw, L. M., Trojanowski, J. Q., et al. (2009). MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers. Brain, 132(Pt 4), 1067–1077.
Shaw, P., Lerch, J. P., Pruessner, J. C., Taylor, K. N., Rose, A. B., Greenstein, D., et al. (2007). Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurology, 6(6), 494–500.
Small, G. W., Mazziotta, J. C., Collins, M. T., Baxter, L. R., Phelps, M. E., Mandelkern, M. A., et al. (1995). Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA, the Journal of the American Medical Association, 273(12), 942–947.
Soininen, H., Partanen, K., Pitkänen, A., Hallikainen, M., Hänninen, T., Helisalmi, S., et al. (1995). Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E epsilon 4 allele. Neurology, 45(2), 391–392.
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the national institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 280–292.
Striepens, N., Scheef, L., Wind, A., Meiberth, D., Popp, J., Spottke, A., et al. (2011). Interaction effects of subjective memory impairment and ApoE4 genotype on episodic memory and hippocampal volume. Psychological Medicine, 41(9), 1997–2006.
Suthana, N. A., Krupa, A., Donix, M., Burggren, A., Ekstrom, A. D., Jones, M., et al. (2010). Reduced hippocampal CA2, CA3, and dentate gyrus activity in asymptomatic people at genetic risk for Alzheimer’s disease. NeuroImage, 53(3), 1077–1084.
Taylor, J. L., Scanlon, B. K., Farrell, M., Hernandez, B., Adamson, M. M., Ashford, J. W., Noda, A., et al. (2014). APOE-epsilon4 and aging of medial temporal lobe gray matter in healthy adults older than 50 years. Neurobiology of Aging [in press].
Thompson, W. K., Hallmayer, J., & O’Hara, R. (2011). Design considerations for characterizing psychiatric trajectories across the lifespan: application to effects of APOE-ε4 on cerebral cortical thickness in Alzheimer’s disease. The American Journal of Psychiatry, 168(9), 894–903.
Tohgi, H., Takahashi, S., Kato, E., Homma, A., Niina, R., Sasaki, K., et al. (1997). Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E epsilon4 allele. Neuroscience Letters, 236(1), 21–24.
Trachtenberg, A. J., Filippini, N., & Mackay, C. E. (2012). The effects of APOE-ε4 on the BOLD response. Neurobiology of Aging, 33(2), 323–334.
Tuminello, E. R., & Han, S. D. (2011). The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations. International Journal of Alzheimer’s Disease, 2011, 726197.
Villemagne, V. L., & Rowe, C. C. (2013). Long night’s journey into the day: amyloid-β imaging in Alzheimer’s disease. Journal of Alzheimer’s Disease, 33(Suppl 1), S349–359.
Villemagne, V. L., Pike, K. E., Chetelat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., et al. (2011). Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Annals of Neurology, 69(1), 181–192.
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., et al. (2013). Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurology, 12(4), 357–367.
Vlassenko, A. G., Mintun, M. A., Xiong, C., Sheline, Y. I., Goate, A. M., Benzinger, T. L. S., et al. (2011). Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C] Pittsburgh compound B data. Annals of Neurology, 70(5), 857–861.
Westlye, E. T., Lundervold, A., Rootwelt, H., Lundervold, A. J., & Westlye, L. T. (2011). Increased hippocampal default mode synchronization during rest in middle-aged and elderly APOE ε4 carriers: relationships with memory performance. The Journal of Neuroscience, 31(21), 7775–7783.
Wierenga, C. E., & Bondi, M. W. (2007). Use of functional magnetic resonance imaging in the early identification of Alzheimer’s disease. Neuropsychology Review, 17(2), 127–143.
Wishart, H. A., Saykin, A. J., McAllister, T. W., Rabin, L. A., McDonald, B. C., Flashman, L. A., et al. (2006). Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. Neurology, 67(7), 1221–1224.
Yi, D., Lee, D. Y., Sohn, B. K., Choe, Y. M., Seo, E. H., Byun, M. S., et al. (2014). Beta-Amyloid Associated Differential Effects of APOE ε4 on Brain Metabolism in Cognitively Normal Elderly. The American Journal of Geriatric Psychiatry: official journal of the American Association for Geriatric Psychiatry [in press].
Conflicts of Interest
None to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fouquet, M., Besson, F.L., Gonneaud, J. et al. Imaging Brain Effects of APOE4 in Cognitively Normal Individuals Across the Lifespan. Neuropsychol Rev 24, 290–299 (2014). https://doi.org/10.1007/s11065-014-9263-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11065-014-9263-8